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ABSTRACT
We measured bone mineral density (BMD) using dual-energy x-ray 
absorptiometry in 20 patients with Cushing’s syndrome (CS) (14 pre- 
and 2 postmenopausal women, 4 men) before and in 18 of them also 
at regular intervals after surgical cure (median duration of follow-up,
36 months). In addition, in the premenopausal women with CS, fast­
ing blood samples and 2-h fasting urine samples for measurement of 
biochemical parameters of bone and collagen metabolism were col­
lected before and in 9 of them also at regular intervals during the first
2 yr after surgery. Marked osteopenia was present in'most patients 
with active CS (Z-scores: lumbar spine -1.45 ± 1,44 and femoral neck 
~ 1.50 ± 1 .02; mean ± sd). No consistent change in BMD was observed 
at 3 and 6 months after surgery. Thereafter BMD increased consid­
erably in almost all patients. For the 15 patients with a follow-up of 
at least 1 yr, Z-scores at the last evaluation were -0.65 ± 1.27 for the 
lumbar spine and -0.98 ± 1.02 for the femoral neck (both/5 < 0.002 
compared with pretreatment values). In the premenopausal patients, 
the increase in BMD both in the lumbar spine and in the femoral neck 
at 24 months was inversely correlated with age (r = -0.733, P < 0.03, 
and r ~ -0.667, P < 0.05, respectively). Serum levels of osteocalcin, 
bone alkaline phosphatase, carboxyterminal propeptide of type I pro­
collagen, aminoterminal propeptide of type III procollagen, and the 
cross-linked telopeptide of type I collagen were not significantly dif­
ferent between the group of 14 premenopausal patients with active CS 
and a control group of 18 age-matched healthy premenopausal 
women. However, the urinary hydroxyproline/creatinine ratio was 
significantly higher in patients with CS (24.6 ± 9.6 vs. 1.6.2 ± 3.5 
/xmol/mmol, P < 0.01). In all 9 premenopausal patients, serum levels 
of osteocalcin increased considerably between 0 and 3 months (from
1.04 ± 0.20 to 3.82 ± 0.30 nmol/L) (mean ± SEM, P < 0.0001), indi­
cating a prompt increase of osteoblast activity. Also serum levels of 
carboxyterminal propeptide of type I procollagen, aminoterminal 
propeptide of type III procollagen, and cross-linked telopeptide of type
I collagen, and the urinary hydroxyproline/creatinine ratio increased 
significantly between 0 and 3 months. Thereafter these levels de­
creased gradually, We conclude that marked osteopenia in the lumbar 
spine and femoral neck is present in most patients with active Cush­
ing’s syndrome, Bone density does not consistently change in the first
6 months after cure, despite an apparently rapid restoration of os­
teoblast activity. Thereafter remarkable improvement of bone density 
can be observed in almost all patients. (J Clin Endocrinol Metab 80:
2859-2865, 1995)
bl« A«*!"1
IN HIS CLASSIC report on endogenous glucocorticoid ex­cess attributable to ACTH-producing pituitary tumors, 
Harvey Cushing recognized osteoporosis as a serious con­
sequence of hypercorticism (1 ). This type of bone loss is more 
m arked in trabecular than in cortical bone and  frequently 
leads to fractures of vertebrae, ribs, and pubic bones (2 ).
In recent years, accurate methods to assess bone mineral 
density (BMD) have become available, making it possible to 
study the reversibility of osteopenia after cure of Cushing's 
syndrome. However, only a small number of longitudinal 
observations on BMD in patients with treated Cushing's 
syndrom e have been reported so far (3, 4). Pocock et aL (3) 
described two patients in whom lumbar and femoral BMD 
increased postopera lively. Unfortunately, in these patients 
no information on BMD before surgery was available. Lufkin 
L’f nl, (4) followed nine patients for 3-66 months after surgery 
and observed a 20% increase in lumbar BMD. However, most
Received April 11, 1995. Accepted May 5, 1995.
Address all correspondence and requests for reprints to: Dr. A. 
Hermus, Department of Medicine, Division of Endocrinology, Univer­
sity Hospital Nijmegen, 6500 HB Nijmegen, The Netherlands.
* Presented in part at the 76th Annual Meeting of The Endocrine 
Society, Anaheim, California, June 15-18, 1994 (Abstract 1045).
subjects had only a single follow-up m easurement, and  BMD 
in the proximal femur was not assessed.
In the present study BMD is evaluated in 20 patients w ith  
active Cushing's syndrome. In 18 of these patients BMD w as 
also measured at regular intervals after surgical cure. D u ­
ration of follow-up in these patients ranged from  3 -60  
months. Fifteen patients were followed for at least 12 m onths 
after successful surgery. In addition, data are presented on 
serum levels of markers of osteoblastic activity and collagen 
synthesis and on serum and urine markers of bone resorption 
before and during the first 2 yr after surgical cure of 
Cushing's syndrome.
Patients and M ethods
Patients
Twenty patients with Cushing's syndrom e participated in this study. 
Informed consent was obtained from all patients. Relevant clinical data 
of the patients is given in Table 1. Patients 1-14 w ere prem enopausal 
wom en (age 29 ± 9 yr, mean ±  s d ), patients 15 and 16 were p ostm en o­
pausal, and patients 17-20 were men.
Six patients (1—5 and 16) had a cortisol-producing adenom a, and 14 
had pituitary-dependent Cushing's syndrom e. Unilateral adrenalec­
tomy was performed in the patients with an adrenal adenoma. After­
ward they received substitution therapy with cortisone acetate, 37.5 m g
2859
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Patient
number
Age
(y r f
Duration of symptomatic 
glucocorticoid excess 
(months)"
Duration of 
amenorrhea (months)0
Body mass index 
(kg/m2)°
Mean 24-h plasma 
cortisol (/j.mol/L)a>6
Duration of follow-up 
after definitive surgery 
(months)
1 33 30 0 22.0 0.40 57
2 19 7 0 26.7 0.69 52
3 23 15 14 29.7 0.62 48
4 42 132 u teru s extirpation 27.3 0.54 27
5 20 36 0 25.6 0.50 24
6 40 27 9 25.8 0.60 60
7 29 14 0 28.7 0.59 52
8 28 23 0 29.9 0.60 40
9 2 2 14 8 23.5 0.66 35
10 23 48 0 42.4 0.48 1 2
1 L 17 15 6 26.9 0.97 18
1 2 41 24 0 38.9 0.66 3
13 32 18* 9 23,6 0.55 0
14 41 48 Q 39.3 0.58 0
15 52 30 168 24,6 0.38 60
16 53 24 36 27.8 0.43 5
17 28f 24 24.9 0.50 48
18 25 1 2 20.3 0,67 36
19 51 36 28.5 0.58 29
20 52 72 25.5 0,64 3
" A t the tim e o f definitive surgery.
b M ean value o f  plasma samples obtained a t 0400, 0800, 1200, 1600, 2000, and 2400 h.
daily, which w as tapered off in the year after surgery and stopped  
between 8 and 1 2  months postoperatively.
Six patients (6 ,10-12,15, and 20) with pituitary-dependent Cushing's 
syndrome were cured by pituitary m icroadenom ectom y via  the trans­
sphenoidal route. This operation caused transient hypocortisolism  in 
patients 6,10 , 11, and 15, necessitating substitution therapy w ith  cor­
tisone acetate for 8 -16  months, but did not induce other endocriner »
deficiencies. Patients 12 and 20 were also liypocortisolem ic after pitu­
itary microadenomectomy, but the short follow-up after surgery does 
not permit conclusions with regard to permanent postoperative endo­
crine deficiencies. Patients 17-19 with pituitary-dependent Cushing's 
syndrom e were cured by (sub-)total adenohypophysectom y via the 
transsphenoidal route. This operation caused permanent secondary hy- 
pocorticism and hypothyroidism, necessitating substitution therapy 
with cortisone acetate and l - thyroxine. Postoperative secondary h ypog­
onadism was present in patients 18 and 19, necessitating treatment with  
im injections of testosterone esters. In addition, postoperative growth  
hormone deficiency was present in all three patients. In patient 19 
substitution therapy with recombinant human grow th  horm one was 
started 21  months postoperatively. Patients 7-9  w ere cured by bilateral 
adrenalectomy, necessitating substitution therapy with glucocorticoids 
and 9ar-fluorohydrocortisone acetate. Previous unsuccessful pituitary 
surgery had not induced deficiencies of pituitary horm ones in  these 
patients. Patients 13 and 14 are awaiting pituitary surgery.
' In all premenopausal patients w ho were amenorrheic before treat­
ment, menses returned within a few months after definite surgical cure. 
At the time of the evaluation of BMD (andof biochemical parameters of 
bone metabolism) before definite surgical therapy, patients 12,15, and
16 used a thiazide diuretic. None of the other patients used  any drugs 
(at this time or in the preceding 3 months) that w ere know n to influence 
bone metabolism, except for patients 5, 7, and 8, w ho used  oral con­
traceptives, which were discontinued 4 weeks before the preoperative 
evaluation.
Methods
BMD measurements. BMD was measured two times before (on 2 con­
secutive days) and at 3 ,6 ,12 ,18 ,24 ,36 ,48 , and 60 m onths after definitive 
surgical treatment BMD was measured in the lumbar spine (LI-14; 
anterior-posterior) and the left femoral neck using dual-energy x-ray 
absorptiometry (Hologic Inc., Waltham MA, m odel QDR-1000). The 
coefficient of variation (CV) for repeat measurements in our hospital is 
1,0% in the lumbar spine and 1,7% in the femoral neck (5). In none of
the patients were fractures of lumbar vertebrae seen on radiographs 
m ade before and 24 months after surgery.
BMD measurements are expressed in g /c m 2. Furthermore, for each 
BMD measurement a Z-score was calculated according to the formula 
Z-score (s d ) = [patient's value (g /c m 2) -  mean of a reference group of 
age- and sex-matched healthy individuals (g /c m 2)] h- s d  reference 
group (g /c m 2).
Results of BMD measurements before and during the first 2 yr after 
surgical treatment in patients 1 ,2 ,3 ,6, and 15 have been reported earlier
(6).
Biochemical measurements. Before surgical therapy in the 14 premeno­
pausal w om en with Cushing's syndrome, blood samples were drawn 
(between 0830 and 0930 h) and 2-h urine sam ples were collected (be­
tween 0800 and 1000 h) after an overnight fast for measurement of 
biochemical parameters of bone and collagen metabolism. In 9 of these 
premenopausal patients (1-9), the parameters (except for bone alkaline 
phosphatase) were also determined at3 , 6, 12, 18, and 24 months after 
definitive surgical treatment. Data were compared with those of a group 
of 18 age-matched healthy premenopausal wom en in the early follicular 
phase of the menstrual cycle.
Blood samples for measurement of serum bone alkaline phosphatase, 
osteocalcin, carboxyterminal propeptide of type I procollagen (PiCP), 
amino terminal propeptide of type III procollagen (PIIINP) and the cross- 
linked telopeptide of type I collagen (ICTP) were centrifuged immedi­
ately after collection. Thereafter, samples were kept at —20 C until 
analyzed. A ll sam ples were run in duplicate. Serum bone alkaline phos­
phatase was assayed by a direct immunoradiometric assay (Ostase, 
Hybritech, San D iego CA) using two monoclonal antibodies directed 
against the bone isoenzym e and with bone alkaline phosphatase purified 
from human osteosarcoma cells as a standard. Intra- and interassay CVs 
were 5% and 7.5%, respectively. Serum osteocalcin was measured by 
RIA (OSTK-PR, CIS, Gif-sur-Yvette Cedex, France; intraassay CV 6%, 
interassay CV 7%). Serum PICP was measured by RIA (PICP RIA-ktt, 
Orion Diagnostica, Espoo, Finland). Intra- and interassay CVs using a 
reference serum sample were 3% and 5%, respectively. Serum PIIiNP 
was determined by RIA (PIIINP RIA-kit, Orion Diagnostica). Intra- and 
interassay CVs using a reference serum sample were 4% and 6%, re­
spectively. Serum ICTP was measured by RIA (ICTP RIA-kit, Orton 
Diagnostica; intraassay CV 4.5%, interassay CV 6%).
Urines w ere not acidified before analysis. Urinary creatinine was 
measured on a Cobas Bio automatic analyzer system  (Roche, Basel, 
Switzerland). Urinary hydroxyproline w as measured with the 
Hypronosticon kit (Organon Teknika, Boxtel, The Netherlands).
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Statistical analyses
Statistical analyses were performed using the Wilcoxon signed rank 
test for paired observations (P values denoted as P), the Mann-Whitney 
U test for unpaired observations (P =  P*) and the Spearman rank cor­
relation test (P =  P**). Unless otherwise stated, the mean values ± 1 s d  
are given.
correlation between BMD (Z-scores) at either site and age, 
duration of symptomatic glucocorticoid excess, du ra tion  of 
amenorrhea, or mean 24-h plasma cortisol in  the g roup  of 
premenopausal patients.
Results
BMD in patients with active Cushing's syndrome
M arked osteopenia was present in most patients with ac­
tive Cushing's syndrom e (Table 2). The decrease in BMD was 
equally severe in the lumbar spine and femoral neck (Z- 
scores: lum bar spine —1.45 ±  1.44 and femoral neck —1.50 ± 
1.02; P > 0.10). In 15 of 20 patients, BMD at one or both sites 
was lower than — 1 s d  and in about half of the patients even 
lower than —2  s d  below the mean value when compared with 
the reference groups of age- and sex-matched healthy indi­
viduals. There was no significant difference in BMD between 
patients with pituitary-dependent Cushing's syndrome (Z- 
scores: lum bar spine —1.56 ± 1.32 and femoral neck —1.76 ± 
0.85) and those with an adrenal adenoma (Z-scores: lumbar 
spine —1.19 ± 1.80 and femoral neck -1.39 ± 1.09).
In the group of 14 premenopausal women, BMD (Z-score) 
in the lum bar spine was significantly correlated with BMD 
in the femoral neck (r = 0.553, P** <0.05). BMD in the lumbar 
spine was also significantly correlated with the body mass 
index (k g /m 2) (r = 0.644, P** <  0.02) in the group of pre­
m enopausal wom en, whereas there was no significant cor­
relation between BMD in the femoral neck and body mass 
index (r =  0.355, P** > 0.10). There was also no significant
BMD after surgical cure of Cushing's syndrome
After surgery no consistent change in BMD was observed 
at 3 and 6 months (Fig. 1). In fact, BMD was lowered by 2% 
or more in comparison with pretreatm ent values at one or 
both time points in 6 of 17 patients at the lum bar spine an d  
in 11 of 16 patients at the femoral neck. In  the group of 
premenopausal women, there w as a highly significant in ­
verse correlation between age and increase in  BMD in the 
lumbar spine in the first 6 months after surgery (r =  —0.925,
P** <  0.0005).
From 6 months onward BMD increased considerably in  
most patients (Fig. 1 ). For the 15 patients w ith  a dura tion  of 
follow-up of at least 1 yr, Z-scores at the time of the last 
evaluation are given in Table 2. At the last evaluation Z- 
scores in these 15 patients were —0.65 ±  1.27 for the lum bar 
spine and -0.98 ± 1.02 for the femoral neck (both P <  0.002 
compared with pretreatment values). W hen com pared w ith  
pre treatment values, BMD at the last m easurem ent had in ­
creased ill the lumbar spine in 12 of 15 patients (in 7 of them  
by more than 15%; increase 22.1% ± 4.8%, n =  7) and  in the 
femoral neck in 11 of 15 patients (in 5 of them  by m ore  than  
15%; increase 22.0% ± 4.0%, n =  5). However, at the last 
measurement, BMD in the lum bar spine was still low er than  
- 1  s d  in 6 of 15 patients and in the femoral neck in 7 of 15 
patients. In the group of prem enopausal patients, the in-
T A B L E  2. Bone m ineral density  (BMD; g/cm2) in the lumbar spine (L1-L4-) and left femoral neck in 20 patients w ith  C u sh in g’s syndrom e  
before and after surgical cure
Patient
number
BMD lumbar spine in g/cm2 
(Z-score in s d )
BMD femoral neck in  g/cm2 
(Z-score in  s d ) Time between definitive surgery 
and last measurement of BMD (months)Before 
definitive surgery“
Last measurement after 
definitive surgery*
Before definitive 
surgery"
Last measurement after 
definitive surgery*
1 0.700 ( -3 .1 8 ) 0.861 ( -1 .5 7 ) 0.633 ( -2 .5 4 ) 0.632 ( -2 .2 9 ) 48
2 0.791 ( -2 .0 8 ) 0.989 ( -0 .4 1 ) 0.661 ( -2 .3 1 ) 0.802 ( -0 .9 3 ) 48
3 1.024 ( -0 .1 0 ) 1.288 ( + 2 .2 2 ) 0.684 ( - 2 .1 2 ) 0.876 ( -0 .1 4 ) 48
4 0.937 ( -0 .7 0 ) 0.933 ( -0 .6 3 ) 0.664 ( -1 .7 7 ) 0.691 ( -1 .3 8 ) 24
5 0.723 ( -2 .7 0 ) 0.931 ( -0 .8 9 ) 0.731 ( -1 .6 4 ) 0.858 ( -0 .3 6 ) 24
6 0.918 ( -0 .9 9 ) 0.986 ( -0 .1 1 ) 0.737 ( -1 .1 5 ) 0.760 ( -0 .6 5 ) 60
7 0.949 ( -0 .7 9 ) 0.927 ( -1 .0 6 ) 0.722 ( -1 .7 6 ) 0.716 ( -1 .5 9 ) 48
8 0.708 ( -3 .0 7 ) 0.707 ( -3 .0 8 ) 0.545 ( -3 .4 4 ) 0.573 ( -3 .1 0 ) 36
9 0.869 ( -1 .4 8 ) 1.031 ( -0 .0 9 ) 0.811 ( -0 .8 3 ) 0.973 (+0 .80) 2 4
10 1.014 ( -0 .1 5 ) 1.067 (+ 0 .26) 0.815 ( -0 .8 0 ) 0.821 ( -0 .7 3 ) 1 2
1 1 0.800 ( -1 .9 0 ) 0.942 ( -0 .6 7 ) 0.720 ( -1 .7 6 ) 0.767 ( -1 .2 8 ) 18
1 2 1.061 ( + 0.39) 0.779 ( - 0 .66)
13 0.757 ( -2 .6 2 ) 0.673 ( -2 .0 9 )
14 0.934 ( -0 .8 0 ) 0.811 ( -0 .3 7 )
15 0.671 ( -2 .5 0 ) 0.771 ( -1 .2 5 ) 0.637 ( -1 .4 3 ) 0.651 ( -0 .9 6 ) 60
16 1 . 1 2 0  (-1-1.60) 0.763 ( -0 .1 5 )
17 0.743 ( -3 .1 7 ) 0.863 ( -2 .0 7 ) 0.623 ( -2 .9 8 ) 0.767 ( -1 .4 2 ) 48
18 0.828 ( - 2 .4 0 ) 0.925 ( -1 .5 1 ) 0.802 ( -1 .4 0 ) 0.782 ( -1 .4 4 ) 36
19 1.130 (+ 0 .74 ) 1.158 (+1 .04) 0.955 (+ 0 .99) 0.919 (+0 .74) 24
20 0.710 ( -3 .0 5 ) 0.649 ( -1 .7 5 )
M ean±SD 0.869 ±  0.147 0.959 ±  0.143 0.721 ±  0.093 0.773 ±  0.109
( - 1 .4 5  ±  1.44) ( - 0 .6 5  ±  1.27) ( - 1 .5 0 ±  1 .0 2 ) ( - 0 .9 8  ±  1.02)
In parentheses BM D is expressed as positive or negative standard deviations from the age- and sex-specific norm al m ean  (Z-score, see  text). 
a M ean of two determ inations.
b V alues of patients w ith  a duration of follow-up of at lea st 12 m onths after definitive surgery are given.
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Fig. 1. Percentage change in BMD in the lumbar sp in e (L1-L4) and femoral neck after surgical cure of 18 patients w ith  C ushing’s syndrome. 
The individual v a lu e s  at seven time points after surgery w ere compared with the pretreatm ent value (t =  0 m onths; m ean of two determinations). 
Note that the im provem ent of BMD in the lum bar spine in patients 7 and 8 is less  th an  that in  the other patients. Both patients used 
glucocorticoids in  doses that were higher than the norm al substitution  dose, and patient 7 w as treated for a m alignant m idline granuloma 9 
months after b ilateral adrenalectomy.
crease in BMD in the lumbar spine at 24 m onths was in­
versely correlated with age (r =  -0.733, P** <  0.03) and 
positively correlated with the increase in BMD in the femoral 
neck at 24 m onths (r = 0.767, P** <  0.03) and w ith  the increase 
in BMD in the lumbar spine at 6 months (r = 0,867, P** <  
0.005). The increase in BMD in the femoral neck at 24 months
was also inversely correlated with age (r
0 .0 5 ) .
0.667, P** <
Biochemical parameters of bone and collagen metabolism in 
premenopausal patients with active Cushing’s syndrome
Serum levels of parameters of osteoblast activity and col­
lagen synthesis (osteocalcin; bone alkaline phosphatase, 
PICP, PIIINP) w ere  not significantly different between the 
group of 14 prem enopausal patients with active Cushing's 
syndrome and  the group of 18 age-matched healthy pre­
menopausal w om en (Table 3). Of the parameters of bone 
resorption, the urinary hydroxyproline/creatinine ratio was 
significantly h igher in patients with Cushing's syndrome,
whereas serum  levels of ICTP were not different between 
both groups.
In the patients with Cushing 's syndrome, serum osteocal­
cin levels were significantly correlated with those of PICP 
(r — 0.645, P** <  0.03) and  those of bone alkaline phosphatase 
(r =  0.639, P** <  0.05). N o other significant correlations were 
observed between the above-mentioned biochemical param­
eters in the group of premenopausal patients with Cushing's 
syndrome. Z-scores in the lum bar spine or the femoral neck 
did  not correlate significantly with any of the biochemical 
parameters of bone and collagen metabolism.
In the group of healthy premenopausal women, serum 
osteocalcin levels were significantly correlated with those of 
PICP (r =  0.602, P** <  0.01) and  of bone alkaline phosphatase 
(r =  0.783, P** <  0.0001), as they were in the patients with 
Cushing's syndrome. In the healthy women, serum PICP 
levels were also correlated w ith serum levels of bone alkaline 
phosphatase (r =  0.737, P** <  0.0003). Unlike the serum levels 
of ICTP in the patients with Cushing's syndrome, serum 
levels of ICTP in the healthy premenopausal women were
TABLE 3. Serum  and urine levels of parameters of bone and collagen m etabolism  in  14 prem enopausal patients w ith  active Cushing’s 
syndrome and in 18 age-m atched healthy prem enopausal women
Cushing’s syndrome Healthy women P-valuea
Serum osteocalcin  (nmol/L) 1.05 ±  0.60 1.28 ±  0.42 N S
Serum bone alkaline phosphatase (fig/L) 12 .6  ±  6.5 9.9  ± 3.7 N S
Serum PICP (jmg/L) 190 ±  99 128 ± 53 N S
Serum PIIIN P (fxg/L) 3.9 ±  2.8 2.6  ±  0.8 N S
Serum ICTP (/xg/L) 3.8 ±  1,6 3.7 ± 1.1 N S
Urine hydroxy proline/creatinine (/¿mol/mmol) 24.6 ±  9.6 16.2 ± 3.5 < 0 .0 1
PICP, C arb oxyter m in  al propeptide of type I pro collagen; PIIINP, amino term inal propeptide of type III pro collagen; ICTP, cross-linked 
telopeptide of type I collagen.
M ann-W hitney U  te s t  (NS, not significant).
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significantly correlated with those of osteocalcin (r =  0.504, 
P** <  0.05), PICP (r = 0.608, P** <  0.01), and bone alkaline 
phosphatase (r = 0.740, P** <  0.0003).
Biochemical parameters o f bone and collagen metabolism  
after surgical cure of premenopausal patients with 
Cushing's syndrome
In nine prem enopausal patients with Cushing's syndrom e 
we determined the above-mentioned parameters, except for 
bone alkaline phosphatase, at regular intervals during the 
first 2 yr after surgical cure (Fig. 2). In all patients, serum  
levels of osteocalcin increased considerably betw een 0 and  3 
months [from 1.04 ± 0.20 to 3.82 ± 0.30 nm ol/L  (mean ±  
s e m ), P <  0.0001], indicating a prom pt increase of osteoblast 
activity. Also serum levels of PICP and PIIINP increased 
significantly between 0 and 3 months [PICP from 173 ± 32 
to 250 ±  35 /¿g/L (mean ± s e m ), P <  0.05, and PIIINP from 
3.14 ± 0.89 to 14.80 ± 1.75 /xg/L (mean ± s e m ), P <  0.0001]. 
Thereafter PICP levels decreased gradually (24 m onths vs, 3 
months, P <  0.05; 24 months vs, healthy controls, P* >  0.10). 
Serum osteocalcin and PIIINP levels also decreased gradu­
ally from 3 months after surgery onward (24 months vs. 3 
months, both P <  0.05), but at 24 months after surgery these 
levels were still elevated when compared with levels in 
healthy women (P* <  0.04 for PIIINP and P* <  0.006 for 
osteocalcin). Of the parameters of bone resorption, the u ri­
nary hydroxyproline/creatinine ratio and serum levels of
ICTP increased in all pa tien ts  betw een 0 and 3 m onths [ICTP; 
from 4.07 ±  0.65 to 14.09 ±  2.30 jug/L  (mean ±  s e m ), P <  0.05;
urinary h y d ro x y p ro lin e /c rea tin in e  ratio: from  27.36 ±  2.85 
to 70.73 ±  7.45 /xmo l /m m o l  (mean ± s e m ), P <  0.0001]. 
Thereafter the u r in a ry  hydroxypro line /crea tin ine  ratio de­
creased g radually  (24 m on ths  vs. 3 months, P <  0.005; 24 
m onths vs. healthy contro ls , P* >  0.10). Serum  ICTP levels 
also decreased g ra d u a lly  from  3 m onths after surgery  on­
w ard (24 m onths vs. 3 m onths, P <  0.05), bu t at 24 m onths 
after surgery these levels  w ere  still elevated w hen  com pared 
with levels in  h ea lthy  w o m en  (P* <  0.05).
D iscussion
In the present s tu d y , m ark ed  osteopenia, equally severe in 
the lum bar spine and  in  the fem oral neck, was dem onstra ted  
by dual-energy x-ray abso rp tiom etry  in m ost patients w ith  
active C ushing 's sy n d ro m e. In a prelim inary  report, 
Mercado-Asis et al. (7), u s in g  the sam e technique as that used  
in our study, em p h asized  th a t the decrease in BMD was m ore 
severe in pediatric  th a n  in  adu lt patients w ith C ushing 's 
syndrome [in ag reem en t w ith  the observation that young  
patients receiving glucocorticoid  therapy lose bone m ore 
rapid ly  than do older p a tien ts  (8)]. In our g roup  of 14 ad u lt  
prem enopausal pa tien ts  w ith  C ushing 's syndrom e, we could 
not dem onstrate a significant correlation betw een  BMD and  
age, nor between BMD a n d  estim ated duration  of sym ptom ­
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F ig . 2. Serum  levels (m ean ±  SEM) of osteocalcin, PICP, PIIIN P and ICTP, and the u rin ary  h y d ro x y  p ro lin e/creatin in e ratio  in  n in e  prem eno­
pausal wom en with C ushing’s syndrome before (t -  0 m onths) and at 3 ,6 , 9,12,18, and 24 m on th s a fte r  su rg ica l cure (blood w a s sa m p led  b etw een  
0830 and 0930 h, and urine w as collected between 0800 and 1000 h  after an overnight fast).
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atic glucocorticoid excess, duration of am enorrhea, and 
mean 24-h plasma cortisol. Interestingly, a significant posi­
tive correlation between BMD in the lumbar spine and  body 
mass index w as observed. Apparently a high body mass 
protects against glucocorticoid-induced bone loss in  the lum ­
bar spine.
The mechanism of the profound decrease of BMD in C ush­
ing's syndrome cannot be derived from our study. It is, 
however, most likely that several factors act together, e.g. the 
detrimental effect of hypercortisolism on bone formation, the 
glucocorticoid-induced decrease of muscular strength lead­
ing to im paired physical activity, and the glucocorticoid- 
induced impairment of the activity of the pituitary-gonadal 
axis and of growth hormone secretion.
Histomorphometric studies in patients treated w ith  glu­
cocorticoids show a marked decrease in the thickness of osteoid 
seams, a low mineral apposition rate as measured by tetracy­
cline labeling, and a reduced mean wall thickness (9,10). These 
findings support the view that glucocorticoid administration 
decreases bone formation because of direct or indirect inhibi­
tion of osteoblast function. Histomorphometric studies in a few 
patients with Cushing's syndrome revealed a similar pattern (3, 
9). In our group of 14 premenopausal patients w ith active Cush­
ing's syndrome, we found normal serum levels of markers of 
osteoblast activity and collagen synthesis. In our opinion the 
normal serum levels of osteocalcin, bone alkaline phosphatase, 
and PICP indicate either that osteoblast activity w ould be nor­
mal in these premenopausal Cushing's patients or that these 
biochemical parameters lack sufficient sensitivity to detect 
small decreases of osteoblast activity in patients with Cushing's 
syndrome at the time of diagnosis. In this respect it has to be 
noted that the mean duration of estimated symptomatic cortisol 
excess in our patients was more than 2.5 yr and that in corti­
costeroid-treated patients bone loss seems to be m ost marked 
during the first 6 -12  months of treatment, w ith  the rate of bone 
loss sharply slowing down or even approaching zero thereafter 
(1 1 ,12). Our data on markers of osteoblast activity are in agree­
ment with those from Ebeling et al (13) w ho found normal 
serum levels of bone alkaline phosphatase and PICP in a group 
of 25 patients with exogenous (n = 10) or endogenous (n =  15) 
glucocorticoid excess. Normal serum levels of PICP in patients 
with Cushing's syndrome were also reported by Piovesan eta l  
(14). In contrast to our data, decreased serum levels of osteo­
calcin in Cushing's syndrome were reported in a number of 
studies (3,13-16).
Histomorphometric studies, which show  an increase in 
trabecular resorption surfaces, and calcium kinetic studies 
suggest that bone resorption is enhanced by  glucocorticoids 
(9,17,18). This increased bone resorption is possibly attrib­
utable to secondary hyperparathyroidism, w hich is m edi­
ated by the negative calcium balance resulting from  the in­
hibitory effect of steroids on both intestinal calcium 
absorption and renal conservation of calcium. In our study  
two supposed indicators of bone resorption w ere m easured. 
We found that the urinary hydroxyproline/creatinine ratio 
was significantly higher in premenopausal patients w ith  
Cushing's syndrome than in healthy prem enopausal 
women, whereas serum levels of ICTP w ere not different in 
both groups. However, it has to be emphasized that the first 
parameter is no t specific for bone resorption because part of
the hydroxyproline in urine could have been derived from 
soft tissue turnover and  repair, whereas the sensitivity and 
specificity of the latter param eter in detecting changes in 
bone resorption is not yet established. Interestingly, param­
eters of bone formation (bone alkaline phosphatase, osteo­
calcin, and PICP) and those of bone resorption (ICTP) are 
positively correlated in  healthy prem enopausal women but 
not in our premenopausal Cushing's patients, suggesting 
uncoupling of bone form ation and resorption in the latter.
In the first 6 months after surgery there was a highly 
significant inverse correlation between age and increase in 
BMD in the lumbar spine, A t 24 months after surgery, such 
a significant inverse correlation between age and the increase 
in BMD was present for bo th  the lum bar spine and the 
femoral neck. Apparently, in  older prem enopausal women 
the im provem ent of osteopenia after cure of Cushing's syn­
drome is less than that in younger women, at least during the 
first 2 y r  after surgery.
It is of interest that in  the first 6 months after surgery BMD 
was lowered by 2 % or more in comparison with pretreatment 
values in  6 of 17 patients in the lum bar spine and in 11 of 16 
patients in the femoral neck. In the group of premenopausal 
women, serum  levels of osteocalcin increased considerably 
to above the normal range in  all patients; these levels re­
mained elevated during the whole period of observation, 
indicating a prom pt and  sustained increase of osteoblast 
activity. In parallel w ith  the increase in osteocalcin levels, 
serum levels of PICP and  PIIINP increased significantly after 
treatment, bu t their increase w as not sustained. Both param ­
eters of bone resorption (serum  ICTP and urinary h y ­
droxyproline/creatinine ratio) also increased significantly 
after surgery and only gradually normalized in the years 
thereafter. We interpret these findings as an expression of 
restoration of the coupling betw een osteoblast and osteoclast 
function after cure of C ushing 's syndrome. It m ay be that in 
such a situation mineralization of newly formed osteoid is 
delayed, thus explaining the decrease in BMD occurring in 
a considerable num ber of patients after cure of Cushing's 
syndrome. However, interpretation of the pattern of the u ri­
nary hydroxyproline/creatinine ratio and the serum  level of 
ICTP has to be cautious in light of the limitations of both 
param eters in detecting bone resorption, especially during 
nonsteady-state conditions. Furthermore, the increase in 
both param eters after treatm ent of Cushing's syndrom e 
might be caused by an increase of soft tissue turnover and 
repair and  not by an increase in bone resorption. Unfortu­
nately, histomorphometric studies in series of patients w ith 
Cushing's syndrome after treatm ent are lacking.
In a cross-sectional study, M anning et a l  (19) found that 
BMD in the himbar spine and  femoral neck in 17 patients 
cured earlier of Cushing's syndrom e (8.6 ±  1.6 yr; mean ± 
s e m ) w as normal. These authors adduced that the regaining 
of bone density is gradual, probably taking approxim ately 10 
yr to become complete. In ou r study (with a m uch shorter 
follow-up), BMD at the time of the last m easurem ent was still 
lower than  — 1 s d  in 6 of 15 patients in the lum bar spine and 
in 7 of 15 patients in the femoral neck. Additional follow-up 
of our patients will determ ine whether BMD will recover 
completely.
We conclude that m arked osteopenia in the lum bar spine
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and femoral neck is present in most patients w ith  active 
Cushing's syndrome. Bone density does not consistently 
change in the first 6 months after cure, despite an apparently 
rapid restoration of osteoblast activity. Thereafter remark­
able improvement of bone density can be observed in  almost 
all patients.
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